Pilot Study of Pembrolizumab and Single-Fraction, Low-Dose, Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 23 Jul 2018 Planned End Date changed from 31 Mar 2021 to 31 May 2021.
- 23 Jul 2018 Planned primary completion date changed from 31 Mar 2021 to 31 May 2021.
- 23 Jul 2018 Status changed from not yet recruiting to recruiting.